Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options. The company reported Q4 2025 net profit of US$17.4 million and raised 2026 net product revenue guidance to US$480 million–US$495 million, with rapid ZORYVE uptake across expanded indications translating into improving profitability.
Cyborg Score Rationale
The company moved to Q4 2025 net profit of US$17.4 million with full-year 2025 revenue of US$376.07 million. Needham & Company LLC raised its target price from $31.00 to $36.00 with a buy rating. Profitability inflection and strong commercial momentum offset market risks.
Top Insights
ZORYVE cream achieved 58% EASI-75 response at Week 4 in infants 3-24 months with mild-moderate atopic dermatitis in the Phase 2 INTEGUMENT-INFANT trial, with sNDA submission planned for Q2 2026.
Arcutis and Kowa terminated their promotion agreement in January 2026, with Arcutis now assuming responsibility for sales and promotion in pediatric and primary care settings.
Patient survey data shows 88% of adults report concern about steroid side effects and only 20% are completely confident in current treatments, indicating market demand for non-steroidal long-term options.
Pipeline includes ARQ-154 (scalp and body psoriasis, seborrheic dermatitis), ARQ-255 (alopecia areata), ARQ-252 (hand eczema, vitiligo), and ARQ-234 (atopic dermatitis).
Named Competitors
JAK Inhibitors (Topical) — Competing topical JAK inhibitor therapies for dermatological inflammation
PDE4 Inhibitors (Topical) — Alternative phosphodiesterase-4 inhibitor options for psoriasis and dermatitis
Systemic Biologics — Injectable/systemic therapies for moderate-to-severe inflammatory skin disease
Recent Developments
(February 2026) Raised 2026 net product revenue guidance to $480M-$495M with Q4 2025 profitability and filed omnibus shelf registration
(February 2026) Q4 2025 revenue of $129.5M; full-year 2025 revenue of $376.07M with net profit of $17.4M
(January 2026) Terminated Kowa Pharmaceuticals promotion agreement for ZORYVE; assuming internal sales responsibility for pediatric and primary care